InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: biopharm post# 271477

Sunday, 09/04/2016 11:52:37 AM

Sunday, September 04, 2016 11:52:37 AM

Post# of 346094
Interesting ...especially Spigel closing remarks and how many at this time back then knew, but could not say anything publically about PS Targeting?

http://www.hcatodayblog.com/2015/04/29/sarah-cannon-featured-on-fox-friends/

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News